Cresset Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$233K Buy
53,952
+23,800
+79% +$139K ﹤0.01% 1624
2026
Q2
$242K Hold
30,152
– – ﹤0.01% 1499
2026
Q1
$242K Hold
30,152
– – ﹤0.01% 1380
2025
Q4
$351K Hold
30,152
– – ﹤0.01% 1224
2025
Q3
$303K Hold
30,152
– – ﹤0.01% 1236
2025
Q2
$526K Buy
30,152
+1,900
+7% +$27.4K ﹤0.01% 908
2025
Q1
$355K Buy
28,252
+500
+2% +$6.02K ﹤0.01% 1233
2024
Q4
$293K Buy
27,752
+3,270
+13% +$45.8K ﹤0.01% 1363
2024
Q3
$355K Hold
24,482
– – ﹤0.01% 1719
2024
Q2
$208K Buy
+24,482
New +$217K ﹤0.01% 1880

Other funds holding SPRY

Cresset Asset Management's SPRY Position: Q3 2026 in Review

Cresset Asset Management increased its ARS Pharmaceuticals (SPRY) stake by 79% in Q3 2026, buying an estimated $139K and bringing the position to 53,952 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Cresset Asset Management first reported a position in SPRY in Q2 2024 and has held it in 10 quarters since. The position peaked at $526K in Q2 2025. 191 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Cresset Asset Management held 53,952 shares of ARS Pharmaceuticals worth $233K as of Q3 2026.
  • Cresset Asset Management bought 23,800 ARS Pharmaceuticals shares in Q3 2026, an estimated $139K.
  • ARS Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q3 2026, its #1624 holding.
  • Cresset Asset Management first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • Cresset Asset Management's ARS Pharmaceuticals position peaked at $526K in Q2 2025.
  • 191 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Cresset Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.